Market evolution: Medical implants (CN 90219090) — 2015–2025

Introduction

This report examines the EU's external trade in CN 90219090 — a residual category covering medical articles and appliances worn, carried, or implanted in the body to compensate for a defect or disability (excluding artificial body parts, hearing aids with their parts and accessories, and complete cardiac pacemakers). Over the 2015–2025 period, EU trade in this product category underwent a pronounced transformation: exports rose by 48.8% to reach €5.19 billion, while imports grew faster in relative terms (+56.8%) to €3.06 billion, yet the EU maintained and expanded a structurally positive trade balance. Behind these headline figures lie three major dynamics: a price-driven expansion in trade values, a significant geographic reorientation of both import sources and export destinations, and a fundamental strengthening of the EU's strategic position as a net exporter and production base for these medical devices.

1. Sustained Growth Fueled by Rising Unit Values and Expanding Domestic Production

The EU's trade in CN 90219090 expanded substantially in value terms across the entire decade, but the composition of that growth reveals important structural characteristics. Quantity growth was comparatively modest, indicating that much of the value expansion was driven by price increases — consistent with a market moving toward higher-value, more technologically sophisticated medical devices.

Export growth was strong but price-driven

EU exports to non-EU countries grew from €3.49 billion in 2015 to €5.19 billion in 2025, a cumulative increase of 48.8%. However, export quantities rose only 16.0% over the same period (from 3,414 tonnes to 3,962 tonnes). The implied unit export price therefore increased by 28.2%, climbing from approximately €1.02 million per tonne to €1.31 million per tonne. This pattern suggests that the EU's export expansion was primarily achieved through value-added growth — more sophisticated or premium products — rather than through volume scaling alone. Export values hit their lowest point at €3.21 billion (likely during the pandemic dip around 2020), before recovering sharply to their 2025 peak.

Import growth outpaced exports in value terms, driven by a sharper price increase

Imports grew from €1.95 billion to €3.06 billion (+56.8%), but import quantities grew by only 5.0% (from 6,965 tonnes to 7,315 tonnes). The resulting unit import price surged by 49.3%, rising from €0.28 million per tonne to €0.42 million per tonne. The divergence between export and import unit prices remains very large — export prices are roughly three times higher than import prices — indicating that the EU specialises in the high-value segment of this market and sources lower-unit-value goods (or components) from abroad.

EU domestic production expanded dramatically

According to PRODCOM-based production data, the value of EU domestic production for this product category surged from €888 million to €3,257 million — a remarkable 267% increase. This production expansion underpins the EU's ability to grow exports while simultaneously serving intra-EU demand, and is a key factor behind the strengthening of the EU's net exporter position. The growth in production capacity also explains the rising export propensity discussed in Section 3.

Sources: Trade overview, Production volumes

2. Geographic Reorientation: Diversifying Export Markets and Rising Asian Import Competition

The 2015–2025 period witnessed notable shifts in the EU's trade geography. On the export side, the EU diversified its customer base away from traditional reliance on the United States and toward faster-growing or emerging markets. On the import side, the most dramatic development was the explosive growth of China and Singapore as suppliers, partially displacing traditional European and North American sources.

The United States remains the dominant partner but its role is evolving differently on each side

The US was the EU's largest single partner for both exports and imports throughout the period. However, the trajectories diverged:

• Imports from the US grew from €1.19 billion to €1.90 billion (+58.9%), maintaining its position as the dominant import source.
• Exports to the US actually declined from €1.42 billion to €1.19 billion (−16.2%), making the US the only major export destination to contract.

This divergence is significant: the EU's bilateral trade surplus with the US in this product category narrowed considerably, suggesting either increased US manufacturing competitiveness, regulatory shifts, or changing procurement patterns in the US healthcare market.

China's emergence as a major import source is the most striking geographic shift

EU imports from China surged by an extraordinary 664%, rising from just €24 million to €187 million. Although China remains far behind the US in absolute terms, its growth rate signals a fundamental shift in the supply landscape. This likely reflects the expansion of Chinese manufacturing capacity for medical device components and consumables, as well as cost-driven sourcing decisions by EU firms. Meanwhile, EU exports to China also grew strongly (+67.2%, from €217 million to €363 million), indicating a two-way deepening of the EU-China medical device trade relationship.

The United Kingdom shows a striking post-Brexit realignment

The UK trade data reveals a dramatic restructuring:

• EU imports from the UK fell by 52.5% (from €60 million to €28 million), reflecting supply chain reconfiguration after Brexit.
• EU exports to the UK surged by 154.7% (from €257 million to €655 million), making the UK the EU's fastest-growing major export market.

This asymmetry suggests that the UK has shifted from being a production/sourcing location to being primarily a demand market for EU-manufactured medical devices. The volatility coefficient for UK import flows was the highest among all major partners (0.85), consistent with structural disruption and adjustment during the Brexit transition.

Other notable developments among top partners

Sources: Top partners by value

The EU's export growth was notably strong toward Norway (+163.1%), Türkiye (+145.2%), and Russia (+131.3%), diversifying the EU's export base beyond its traditional Western markets.

Export concentration declined sharply, confirming diversification

The Herfindahl-Hirschman Index (HHI) for EU exports by value fell from 1,902 to 1,053 (−44.6%), moving from a moderately concentrated to a well-diversified structure. Import concentration remained higher (HHI of 4,023 in 2025), reflecting the continued dominance of the US as a supplier, though it too declined slightly (−4.4%). The contrast between the two flows underscores that the EU has been more successful at diversifying its export markets than its import sources.

3. The EU's Strengthening Strategic Position: Toward Export Specialisation and Self-Sufficiency

Perhaps the most consequential development over the 2015–2025 period is the fundamental transformation of the EU's strategic position in this market. A combination of surging domestic production, rising export propensity, and shifting net import reliance indicates that the EU has evolved from a market with moderate import dependence to one with a strong net-export orientation.

The EU shifted from net importer to strong net exporter

The net import reliance indicator moved from +53.0% in 2015 to −97.6% in 2025. A positive value indicates a net importing position (imports exceed what domestic production can supply for external markets), while a negative value indicates a net exporting surplus. The swing of 284 percentage points over the decade — reaching an extreme trough of −463% in an intermediate year — reflects the combined effect of tripling production capacity and growing export volumes far beyond import growth.

Export propensity surged, reflecting the EU's competitive repositioning

The export propensity (extra-EU exports as a share of EU production value) rose from 47.6% to 140.1% (+194.2%). A value above 100% means the EU exports more than it produces domestically for this CN code — which may reflect re-export activity through EU trade hubs (notably the Netherlands and Belgium) or temporal mismatches in production and trade reporting. In either case, the upward trajectory confirms the EU's role as a major global supplier.

Trade intensity deepened

The trade intensity (extra-EU trade as a share of production) grew from 79.9% to 121.0% (+51.5%), indicating that the EU's medical implant sector is deeply integrated into global value chains and increasingly oriented toward international markets.

Ireland and the Netherlands anchor the EU's export specialisation

The specialisation analysis for 2025 reveals a concentrated landscape of export advantage:

Ireland shows the highest specialisation (RCA of 7.12), consistent with its well-documented role as a hub for medical technology manufacturing and the presence of major multinational device companies. The Netherlands' strong RCA (2.43) and dominant export share (35.3%) likely reflect its role as a logistics and distribution hub. Germany, while the largest EU economy, shows an RCA close to parity (1.00), indicating that its exports in this category are roughly proportional to its overall export profile.

EU Member State trade hubs drove the expansion

Among EU reporters, the most dramatic growth came from:

• The Netherlands: exports more than doubled (+133.0%, from €628 million to €1,463 million); imports nearly doubled (+112.6%).
• Germany: exports grew +60.6% (from €609 million to €978 million).
• Italy: exports surged +143.9% (from €27 million to €66 million), and imports grew +137.9%.
• France saw a striking decline in imports (−79.4%, from €126 million to €26 million), potentially indicating reshoring or sourcing shifts.

Conclusion

The EU's trade in medical implants and appliances (CN 90219090) over the 2015–2025 decade tells a story of robust growth, geographic diversification, and strategic strengthening. Total extra-EU trade flows expanded well above the rate of quantity growth, driven by rising unit values that reflect the sector's movement toward more sophisticated, higher-value-added products. The EU's domestic production tripled in value, supporting a fundamental shift from a position of moderate net import reliance (+53%) to a strong net exporter status (−98%).

Geographically, the most significant developments were the explosive growth of Chinese and Singaporean imports (+664% and +635% respectively), the post-Brexit reorientation of UK trade, and the diversification of EU export destinations toward Türkiye, Norway, and Russia. Meanwhile, the concentration of EU exports declined sharply (HHI −44.6%), confirming a deliberate or emergent strategy of market diversification. Key risks to monitor include the growing import dependence on a small number of Asian suppliers, the continued reliance on the United States as the single largest import source (with a moderately volatile trade relationship), and the question of whether the EU's strong export performance can be sustained as global competition in medical device manufacturing intensifies.